Beyond PD-1: The Rise of Anti-LAG-3 Antibody LBL-007 in Fighting Nasopharyngeal Carcinoma

The Next Frontier in Cancer Immunotherapy

For over a decade, the landscape of oncology has been dominated by inhibitors targeting the PD-1/PD-L1 and CTLA-4 pathways. While these therapies have revolutionized the treatment of numerous cancers, many patients—particularly those with advanced or recurrent solid tumors—eventually experience disease progression. This has led scientists to hunt for the third checkpoint, a molecule that could reignite the immune system’s fight against cancer. Enter LAG-3 (Lymphocyte Activation Gene-3).

Understanding the LAG-3 Mechanism